U.S. markets closed
  • S&P Futures

    4,206.50
    -16.50 (-0.39%)
     
  • Dow Futures

    33,914.00
    -103.00 (-0.30%)
     
  • Nasdaq Futures

    13,896.00
    -85.25 (-0.61%)
     
  • Russell 2000 Futures

    2,299.80
    -10.30 (-0.45%)
     
  • Crude Oil

    71.49
    -0.66 (-0.91%)
     
  • Gold

    1,819.30
    -42.10 (-2.26%)
     
  • Silver

    27.23
    -0.58 (-2.09%)
     
  • EUR/USD

    1.1996
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3982
    -0.0004 (-0.03%)
     
  • USD/JPY

    110.7600
    +0.1470 (+0.13%)
     
  • BTC-USD

    38,347.89
    -1,721.41 (-4.30%)
     
  • CMC Crypto 200

    949.57
    -42.90 (-4.32%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    0.00 (0.00%)
     

KeyBanc Upgrades Catalent On Industry Transformation

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets.

The Catalent Analyst: Paul Knight upgraded Catalent from Sector Weight to Overweight with a $120 price target. 

The Catalent Thesis: An accelerating number of biotech therapies are being approved by the FDA, easily doubling the pace seen in 2000-2010, Knight said in an upgrade note.

Amid this trend, contract development and manufacturing organizations “have become of increasing strategic importance to biopharma as companies rationalize their supply chain and molecules become increasingly complex to develop and manufacture” the analyst said. 

Catalent's biologic capabilities previously lacked an integrated offering and scale, he said.

“The acquisition of Cook Pharmica in 2017 brought increased scale and technological capability into CTLT's network. Further with 1,109 CGT Clinical Trials ongoing and 5 approved by the FDA, CTLT gained exposure to this end market with acquisitions Paragon Bioservices, and MasTHerCell,” Knight said.   

“Management's recent organic and inorganic investments lead us to believe that its long-term outlook of 6-8% is not only achievable but conservative.” 

CTLT Price Action: Shares of Catalent were up 4% at $96.01 at last check Thursday.

Latest Ratings for CTLT

Dec 2020

KeyBanc

Upgrades

Sector Weight

Overweight

Nov 2020

Morgan Stanley

Maintains

Overweight

Sep 2020

Morgan Stanley

Maintains

Overweight

View More Analyst Ratings for CTLT
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.